Savara Receives FDA Three-Month Extension for Molgramostim Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy SVRA?
Savara "announced that the FDA has extended the review period for the molgramostim BLA in autoimmune PAP by three months. The Agency is reviewing the molgramostim BLA under Priority Review and the new PDUFA target action date is November 22, 2026. The FDA determined that the Company's responses to recent information requests by the Agency constituted a major amendment to the BLA, resulting in a three-month extension of the PDUFA date. The Agency did not cite any safety, efficacy, or manufacturing concerns in their correspondence. This extension allows the FDA additional time to complete their review of the BLA, including recently submitted materials related to information requests."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SVRA
Wall Street analysts forecast SVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.780
Low
9.00
Averages
10.17
High
11.00
Current: 5.780
Low
9.00
Averages
10.17
High
11.00
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Savara Inc. Grants Inducement Awards to New Employees
- Inducement Awards Granted: On April 14, 2026, Savara Inc. granted inducement awards to 24 new employees, comprising 18,500 stock options, 141,000 restricted stock units (RSUs), and 85,000 performance stock units (PSUs), aimed at attracting talent and enhancing employee loyalty.
- Stock Option Details: The granted options have an exercise price of $6.07 per share, matching the closing price on the grant date, with vesting occurring quarterly at a rate of 1/16th of the shares, ensuring continued employment for benefit acquisition.
- RSUs and PSUs Vesting: The RSUs will fully vest on the two-year anniversary of the employee's start date, while PSUs will vest upon the company reporting quarterly revenue exceeding a specified target, aligning employee incentives with company performance.
- Company Background: Savara focuses on clinical-stage biopharmaceuticals for rare respiratory diseases, with its lead product MOLBREEVI in Phase 3 development, demonstrating the company's commitment and capability to address unmet medical needs.
See More
Savara's FDA Review Period Extended for Molgramostim
- Review Period Extension: Savara announced that the FDA has extended the review period for its biologics license application (BLA) for molgramostim inhalation solution by three months, with a new target action date of November 22, up from the original August 22, indicating the FDA's attention to the application.
- Significant Amendment Impact: The FDA noted that Savara's responses to a recent information request represented a major amendment to the BLA, prompting the review period extension, which reflects the company's efforts to meet regulatory requirements.
- No Safety Issues: The FDA did not cite any issues related to the safety, efficacy, or manufacturing of molgramostim in its communications, providing Savara with a positive signal regarding the product's potential market outlook.
- Additional Review Time: This extension allows the FDA additional time to complete its review of the BLA, including recently submitted materials related to information requests, which may help expedite the final approval process.
See More
Savara's FDA Review for Molgramostim Delayed by Three Months
- FDA Review Delay: Savara's application for the experimental therapy molgramostim for Autoimmune Pulmonary Alveolar Proteinosis has seen its FDA review extended by three months, with the new decision deadline set for November 22, which may impact market expectations for the company.
- Major Amendment Submitted: The recent responses submitted by Savara to the FDA have been classified as a major amendment to the application, and while no safety, efficacy, or manufacturing concerns were cited, the additional review time could affect the approval timeline, potentially leading to decreased investor confidence.
- Market Opportunity: If approved, molgramostim could become the first and only therapy for Autoimmune PAP, following a previous refusal to file by the FDA in May 2025 due to insufficient data, indicating Savara's renewed confidence in the product with this resubmission.
- Muted Market Reaction: Despite SVRA stock doubling over the past 12 months, retail sentiment on Stocktwits remains neutral with low message volume, reflecting cautious investor reactions to the FDA review delay, which may affect short-term stock performance.
See More
Savara's Drug Review Period Extended to November 2026
- Review Period Extension: The FDA has extended the review period for Savara's molgramostim BLA by three months to November 22, 2026, as the company's responses to recent information requests were deemed a major amendment, allowing the FDA additional time to complete its review, which could impact the drug's market entry timeline.
- Priority Review Status: Molgramostim has received Priority Review, Fast Track, and Breakthrough Therapy designations in the U.S., along with Orphan Drug Designation in the EU and UK, indicating its potential in treating autoimmune pulmonary alveolar proteinosis and possibly providing Savara with a competitive market advantage.
- Disease Background: Autoimmune pulmonary alveolar proteinosis is a rare lung disease where patients cannot effectively clear surfactant due to GM-CSF neutralization by autoantibodies, leading to impaired gas exchange; Savara's molgramostim aims to stimulate macrophages to address this issue, highlighting its clinical significance.
- Management Team Expertise: Savara's management team possesses extensive experience in rare respiratory diseases and pulmonary medicine, focusing on identifying unmet medical needs and effectively advancing product candidates to approval and commercialization, which may enhance the company's overall value through the successful launch of molgramostim.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
Savara Inc. Grants Inducement Awards to New Employees
- Inducement Awards Granted: On April 14, 2026, Savara Inc. granted inducement awards to 24 new employees, comprising 18,500 stock options, 141,000 restricted stock units (RSUs), and 85,000 performance stock units (PSUs), aimed at attracting talent and enhancing employee loyalty.
- Stock Option Details: The granted options have an exercise price of $6.07 per share, matching the closing price on the grant date, with vesting occurring quarterly at a rate of 1/16th of the shares, ensuring continued employment for benefit acquisition.
- RSUs and PSUs Vesting: The RSUs will fully vest on the two-year anniversary of the employee's start date, while PSUs will vest upon the company reporting quarterly revenue exceeding a specified target, aligning employee incentives with company performance.
- Company Background: Savara focuses on clinical-stage biopharmaceuticals for rare respiratory diseases, with its lead product MOLBREEVI in Phase 3 development, demonstrating the company's commitment and capability to address unmet medical needs.
See More
Savara's FDA Review Period Extended for Molgramostim
- Review Period Extension: Savara announced that the FDA has extended the review period for its biologics license application (BLA) for molgramostim inhalation solution by three months, with a new target action date of November 22, up from the original August 22, indicating the FDA's attention to the application.
- Significant Amendment Impact: The FDA noted that Savara's responses to a recent information request represented a major amendment to the BLA, prompting the review period extension, which reflects the company's efforts to meet regulatory requirements.
- No Safety Issues: The FDA did not cite any issues related to the safety, efficacy, or manufacturing of molgramostim in its communications, providing Savara with a positive signal regarding the product's potential market outlook.
- Additional Review Time: This extension allows the FDA additional time to complete its review of the BLA, including recently submitted materials related to information requests, which may help expedite the final approval process.
See More
Savara's FDA Review for Molgramostim Delayed by Three Months
- FDA Review Delay: Savara's application for the experimental therapy molgramostim for Autoimmune Pulmonary Alveolar Proteinosis has seen its FDA review extended by three months, with the new decision deadline set for November 22, which may impact market expectations for the company.
- Major Amendment Submitted: The recent responses submitted by Savara to the FDA have been classified as a major amendment to the application, and while no safety, efficacy, or manufacturing concerns were cited, the additional review time could affect the approval timeline, potentially leading to decreased investor confidence.
- Market Opportunity: If approved, molgramostim could become the first and only therapy for Autoimmune PAP, following a previous refusal to file by the FDA in May 2025 due to insufficient data, indicating Savara's renewed confidence in the product with this resubmission.
- Muted Market Reaction: Despite SVRA stock doubling over the past 12 months, retail sentiment on Stocktwits remains neutral with low message volume, reflecting cautious investor reactions to the FDA review delay, which may affect short-term stock performance.
See More
Savara's Drug Review Period Extended to November 2026
- Review Period Extension: The FDA has extended the review period for Savara's molgramostim BLA by three months to November 22, 2026, as the company's responses to recent information requests were deemed a major amendment, allowing the FDA additional time to complete its review, which could impact the drug's market entry timeline.
- Priority Review Status: Molgramostim has received Priority Review, Fast Track, and Breakthrough Therapy designations in the U.S., along with Orphan Drug Designation in the EU and UK, indicating its potential in treating autoimmune pulmonary alveolar proteinosis and possibly providing Savara with a competitive market advantage.
- Disease Background: Autoimmune pulmonary alveolar proteinosis is a rare lung disease where patients cannot effectively clear surfactant due to GM-CSF neutralization by autoantibodies, leading to impaired gas exchange; Savara's molgramostim aims to stimulate macrophages to address this issue, highlighting its clinical significance.
- Management Team Expertise: Savara's management team possesses extensive experience in rare respiratory diseases and pulmonary medicine, focusing on identifying unmet medical needs and effectively advancing product candidates to approval and commercialization, which may enhance the company's overall value through the successful launch of molgramostim.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
